Nachrichten zur Vertex Pharmaceuticals Aktie

Am 07. März 2025 gab Vertex Pharmaceuticals Inc. bekannt, dass die britische Regulierungsbehörde für Arzneimittel und Gesundheitsprodukte (MHRA) die Zulassung…

2025 has gotten off to a choppy start as some of the most valuable U.S.-based companies are dragging down the…

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the…

Dr. Reshma Kewalramani, Vertex Pharmaceuticals CEO, leads the first biotech to win approval for a therapy using CRISPR gene editing…

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks…

Looking for a good area in which to invest? Consider the healthcare sector. People must have healthcare. And with aging…

If youre content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not,…

Vertex Pharmaceuticals (NASDAQ: VRTX) and AstraZeneca (NASDAQ: AZN), two of the worlds leading drugmakers, missed last years strong market rally.…

Healthcare isnt the hottest sector these days. While the S&P 500 has soared nearly 21% over the last 12 months,…

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for…

Vancouver (www.aktiencheck.de) - Rating-Update: Canaccord hat die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol: VX1, NASDAQ-Symbol: VRTX) von…

On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the…

New York (www.aktiencheck.de) - Rating-Update: Terence Flynn, Analyst von Morgan Stanley, stuft die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN:…

Heres our initial take on Vertex Pharmaceuticals (NASDAQ: VRTX) fourth-quarter financial report. Key Metrics Metric Q4 2023 Q4 2024 Change vs. Expectations Revenue $2.52 billion $2.91 billion 16% Beat Earnings per share $3.71 $3.50 -6% Missed Trikafta/Kaftrio…

Das US-Biotech-Unternehmen Vertex Pharmaceuticals hat am Montag nach US-Börsenschluss seine Zahlen für das vierte Quartal vorgelegt. Beim Umsatz konnte Vertex…

Das US-Biotech-Unternehmen Vertex Pharmaceuticals hat am Montag nach US-Börsenschluss seine Zahlen für das vierte Quartal vorgelegt. Beim Umsatz konnte Vertex…

VRTX earnings call for the period ending December 31, 2024.…

…

Vertex (VRTX) delivered earnings and revenue surprises of -0.25% and 5.16%, respectively, for the quarter ended December 2024. Do the…

These are the stocks posting the largest moves in extended trading.…

Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its cystic fibrosis…

Investing in stocks that arent performing well can be a good move, but only if there are good reasons to…

…

Equity markets performed well in January, as they often do, but as the dust settles on that early-year run, the…

Vertex Pharmaceuticals SWOT analysis: biotech giants stock faces growth challenges…

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.…

Some people are fair-weather friends; others are lifelong. Its a similar story with stocks. Some you might hold only temporarily,…

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On…

Lately, one of Americas leading pharmaceutical companies cant catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX)…

…

Vertex Pharmaceuticals’ non-opioid painkiller comes without the potential risk of addiction.…

Die US-Arzneimittelbehörde FDA hat das das nicht-opioide Schmerzmittel von Vertex Pharmaceuticals zur Behandlung akuter Schmerzen zugelassen, wie die Gesundheitsbehörde am 30.01.2025…

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds. Rising interest…

Some people make it a New Years resolution to improve their finances by investing in stocks. Its a laudable goal,…

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds up…

Many products sold by companies arent must-have items. However, healthcare is a necessity. And the healthcare sector is poised to…

You can look at the momentum for some stocks and have a feeling that its about to end. Others, though,…

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this…

It usually doesnt matter if you buy a given stock immediately or two weeks later. Sure, the stock could move…

New York (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von J.P. Morgan Securities: Rating und Kursziel JPMorgan analyst Jessica Fye bewertet die Aktie von Vertex…

If youre an investor searching for the next big market winners, Wall Street analysts have zeroed in on one biotech…

Arguably the three most important words in investing are: I dont know. Acknowledging that you dont know for sure what…

The stock market is divided into sectors, with each group of stocks having commonalities with each other, usually because they…

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have…

…

Every investor has heard the phrase "buy low, sell high." Its a simple enough piece of advice thats less simple…

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from…

Warren Buffetts mentor Benjamin Graham once said, "In the short run, the market is a voting machine but in the…

Charlotte, NC (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von Truist: Truist hat das Kursziel für die Aktie von Vertex Pharmaceuticals Inc. (ISIN: US92532F1003,…

Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von der Scotiabank: Aktuelle Bewertung Scotiabank hat das Kursziel für Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807,…